A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

NCT01715285 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1209

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Neoplasms

Interventions

DRUG: Abiraterone acetate
DRUG: Prednisone
OTHER: Androgen deprivation therapy (ADT)
DRUG: Abiraterone acetate Placebo
DRUG: Prednisone Placebo

Sponsor

Janssen Research & Development, LLC